Swiss stocks rise as U.S. yields ease

The SMI rose 0.22% to 14,394.77 points, after trading between 14,321.44 and 14,446.74. The SLI gained 0.23% and the SPI added 0.2%. Fifteen of the SMI’s 30 blue chips advanced, 14 fell and Novartis was unchanged.

The tone was set by New York, where the Dow Jones, S&P 500 and Nasdaq were up between 1% and 1.33% in late trade, helped by reassurance from a Federal Reserve governor and a pause in the sharp rise in debt-market yields. That easing of rate pressure came even as U.S. trade data showed the July deficit widened to $88.6 billion, the highest in more than a year, underlining how sensitive markets remain to any sign the economy is cooling without forcing the Fed into a more aggressive stance.

For investors, the key takeaway is that Swiss equities are still behaving like a high-quality proxy for global risk sentiment. When yields soften, the market is willing to pay up again for earnings resilience, pricing power and balance-sheet strength — all areas where Switzerland is heavily represented.

Individual movers reinforced that pattern. Logitech led the SMI with a 3.3% gain, followed by Givaudan and Sandoz. Roche added 2% after striking a deal with China’s Simcere for rights to an antibody candidate that could reach up to $1.5 billion in payments, while Holcim and Sika also advanced after deal activity. On the downside, Richemont was the day’s laggard, falling 3.1%, with VAT Group, Galderma and Alcon also lower.

The macro backdrop in Switzerland was mixed but supportive enough for equities. GDP accelerated 1.5% in the second quarter and UBS lifted its growth forecasts for 2026 and 2027, while August inflation rose 0.8% year on year, largely because of energy. That combination points to an economy that is not overheating, but is also not weak enough to disrupt corporate earnings expectations.

The opportunity remains in selectively buying Switzerland on dips when global rates retreat. If U.S. inflation data next week keeps the Fed from sounding more hawkish, the SMI has room to extend its rebound, with industrials, healthcare and select consumer names likely to benefit first. For now, the market is telling investors to stay invested in quality and use any further rate-driven volatility to build positions rather than chase fear.